Altimmune Pemvidutide IMPACT Phase 2b Week 48 Oral Presentation (May 28, 17:00 CEST): 1.8 mg Dose Cuts Triglycerides 23.7%, Total Cholesterol 15.4%, Weight 7.5%, Waist 5.3 cm at ~1% Discontinuation
Altimmune presented the full Week 48 top-line IMPACT Phase 2b oral data for pemvidutide in MASH today at EASL 2026 Barcelona (Dr. Mazen Noureddin, Houston Methodist Hospital, 17:00 CEST). The 1.8 mg dose reduced triglycerides 23.7%, total cholesterol 15.4%, body weight 7.5%, BMI 3.0 kg/m², and waist circumference 5.3 cm, alongside blood pressure reduction. Safety held at 48 weeks with roughly 1% discontinuation due to adverse events and mostly mild-to-moderate gastrointestinal events. Previously reported: 27.8% (1.2 mg) and 32.4% (1.8 mg) of patients achieved combined ELF and LSM improvements versus 3.2% on placebo. The 48-week analysis carries the 'Best of EASL 2026' designation. Pemvidutide is a balanced 1:1 GLP-1/glucagon dual receptor agonist peptide with FDA Fast Track + Breakthrough Therapy Designations for MASH. The cardiometabolic-risk-factor profile positions pemvidutide as differentiated on the lipid and cardiovascular axis versus pure GLP-1 agonists.